Numerous neurodegenerative diseases are characterized by the accumulation of tau aggregates. There are 20 known tauopathies; Alzheimer’s disease is by far the most prevalent (5.8 million in the US). The others are generally rare diseases with US prevalence ranging from 50-60 thousand for frontotemporal dementia (FTD) and 10 – 20 thousand for most others.

Targeting tau oligomers can lead to the development of effective treatments for these diseases.